These real-world findings serve an important and complementary role in helping to validate the results seen in EMERALD among patients exposed to 1 to 2 prior lines of endocrine therapy, with or without coexisting tumor mutations beyond ESR1, and support the routine clinical use of elacestrant in select patients. The gene discussed is ESR1; the disease is neoplasm.